Unitil (NYSE:UTL) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.23 by 30.43 percent. This is a 66.67 percent increase over earnings of $0.18 per share from the same period last year.
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate
Adial Pharmaceuticals Inc’s (NASDAQ:ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain.…